Daniel Laheru, MD
Medical Oncology · Baltimore, MDNPI 1497796510
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,135 of the $2,447 with a category attached, or 87.2%. Merck accounts for 87.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $2,285 and has fallen 99.0% since, to $22 in 2024. That places this record below the midpoint for medical oncology clinicians in MD, where the typical reported total is $4,199.
Across 6 payments — averaging $407.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- AstraZeneca$121
- E.r. Squibb & Sons, L.L.C.$120
- AbbVie$71
Across 34 payments — averaging $18,439 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$404K
- Astrazeneca UK Limited$103K
- Exelixis Inc.$100K
- Pfizer$19K
What the payments were for
- Consulting fees$2,13587%
- Food & beverage$31213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $2,135 |
| AstraZeneca | 1 | $121 |
| E.r. Squibb & Sons, L.L.C. | 1 | $120 |
| AbbVie | 3 | $71 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$121
How this compares
$2,447 in reported general payments places this provider in the 45th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 22 | $375 |
| Dexamethasone | 16 | $306 |
| LoperamideLoperamide Hcl | 18 | $269 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.